1. A new strategy for the light-control of β1 -AR activation has been developed using photoswitchable drugs with a high level of β1 -/β2 -AR selectivity.
2. The binding of the best hit, pAzo-2, can be reversibly photocontrolled and enables dynamic cardiac rhythm management on living zebrafish larvae using light.
3. This work provides the first proof of precise control of the therapeutic target β1 -AR in native environments using light.
The article is reliable and trustworthy as it is published in a reputable journal (Angewandte Chemie International Edition) and is written by authors who are experts in their field (Anna Duran-Corbera et al.). The article presents evidence to support its claims, such as confocal microscopy demonstrating that the binding of pAzo-2 can be reversibly photocontrolled, and experiments on living zebrafish larvae showing that pAzo-2 enables dynamic cardiac rhythm management using light. The article also includes detailed descriptions of the methods used to test the efficacy of pAzo-2, such as UV/Vis absorption spectra and 1H‐NMR measurements.
The article does not appear to have any biases or one-sided reporting; it presents both sides equally and does not make any unsupported claims or omit any points of consideration. It also does not contain any promotional content or partiality towards any particular viewpoint. Furthermore, possible risks associated with using pAzo-2 are noted in the article, such as potential toxicity due to its chemical structure. In conclusion, this article is reliable and trustworthy due to its scientific rigor and lack of bias or one-sided reporting.